July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
124 citations
,
January 1993 in “The Prostate” Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
25 citations
,
April 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
July 2025 in “International Journal of Trichology” Oral tofacitinib may effectively regrow hair in children with alopecia areata unresponsive to other treatments.
8 citations
,
October 2002 in “Journal Of Clinical Periodontology” Levamisole and finasteride can reduce DHT production, potentially preventing phenytoin-induced gum overgrowth.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
2 citations
,
July 2020 in “Journal of Drug Delivery Science and Technology” Created finasteride complex to increase water solubility and drug release.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
30 citations
,
March 2016 in “European Journal of Pharmaceutical Sciences” Optimized film improves finasteride skin absorption and treatment efficiency.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
February 2020 in “Bulletin of Experimental Biology and Medicine” Finasteride and GIZh-72 reduce inflammation, with GIZh-72 being more effective.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
January 2011 in “Reactions Weekly”
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
13 citations
,
January 2018 in “International Journal of Trichology” Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
1 citations
,
January 2024 in “Journal of molecular structure” The new finasteride delivery system using chitosan-based nanoniosomes shows promise for prostate cancer prevention.
3 citations
,
April 2021 in “Journal of Medicinal Chemistry” Finasteride may affect PNMT, causing side effects.
January 2004 in “Europe PMC (PubMed Central)” Finasteride sustained-release tablets are stable.
84 citations
,
July 2008 in “Aaps Pharmscitech” Ethosomes improve finasteride delivery through skin for hair loss treatment.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
December 2018 in “Reactions Weekly” Some medications may cause lasting sexual dysfunction.
3 citations
,
November 2017 in “International Journal of Pharmacy and Pharmaceutical Sciences” November 2010 in “International Journal of Developmental Neuroscience”
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.